Skip to content
Search

Latest Stories

Chiesi Farmaceutici acquires Amryt Pharma to develop innovative treatment for rare diseases

Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases.

More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment.


The acquisition reinforces Chiesi’s commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet.

Chiesi’s Head of Chiesi Global Rare diseases Giacomo Chiesi commented: “We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development.

Chiesi’s new CEO Giuseppe Accogli said: “By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases.

With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.

The loan agreement allows the borrower to opt to link the interest rate to some sustainability targets (KPIs) to be set with the advise of the ESG Structuring Banks. KPIs – this is the rationale of the option scheme – will be set with respect to the new perimeter of Chiesi Group, i.e. including Amryt.

More For You

Antibiotic prescribing for sore throats in England's pharmacies is twice as high as in Wales

Antibiotic supply rate was 72.7% under England’s Acute Sore Throat Pharmacy First compared to just 29.9% under Wales’ Sore Throat Test and Treat (STTT) scheme in six months.

Getty Images

Sore throat treatment: England pharmacies twice as likely to prescribe antibiotics as Welsh counterparts

A new study has highlighted significant differences in antibiotic use for sore throat treatment between pharmacies in England and Wales, suggesting that incorporating throat swabs to confirm bacterial infections could help reduce “unnecessary antibiotic supply.”

The study, published in the Journal of Antimicrobial Chemotherapy and first reported by The Independent, found that pharmacies in England were twice as likely to prescribe antibiotics for sore throats compared to those in Wales.

Keep ReadingShow less
GPs to play crucial role in transforming Wales’ health service

Jeremy Miles

(Photo credit: www.gov.wales )

Strengthening GPs’ role key to transforming healthcare - Jeremy Miles

Welsh health secretary Jeremy Miles has recognised the need to transform health services and bring healthcare closer to home.

Speaking at the recent Welsh Local Medical Committees Conference, he emphasised that strengthening the role of GPs would be crucial in improving patient healthcare and tackling NHS waiting lists.

Keep ReadingShow less
NPA and IPA urge NHS England to release pharmacy economic analysis immediately

Pharmacy bodies call for transparency on the funding gap amid ongoing contract negotiations.

Getty Images

Pharmacy bodies demand immediate release of economic analysis

The National Pharmacy Association (NPA) and the Independent Pharmacies Association (IPA) have jointly written to NHS England, demanding the immediate release of the independent economic analysis of pharmacy finances commissioned last autumn.

An open letter, signed by the owners of 3,034 pharmacies in England, calls for transparency on the funding gap amid ongoing contract negotiations.

Keep ReadingShow less
Discrimination: Asian and Black patients report lack of trust in primary care providers

Ethnic minority groups had worse experiences in their communication with their GP practice and felt taken less seriously

Getty Images

Survey reveals alarming rates of ethnic discrimination in NHS primary care

A recent survey by the NHS Race and Health Observatory has highlighted a worrying lack of trust in NHS primary care services among Black, Asian, and ethnic minority patients, who reported experiencing “racial or ethnic discrimination.”

Out of 2,680 survey respondents, only 55% reported trusting primary care providers to meet their health needs most or all of the time

Keep ReadingShow less